CA2326654C - Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways - Google Patents

Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways Download PDF

Info

Publication number
CA2326654C
CA2326654C CA2326654A CA2326654A CA2326654C CA 2326654 C CA2326654 C CA 2326654C CA 2326654 A CA2326654 A CA 2326654A CA 2326654 A CA2326654 A CA 2326654A CA 2326654 C CA2326654 C CA 2326654C
Authority
CA
Canada
Prior art keywords
hedgehog
cells
alkyl
shh
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2326654A
Other languages
English (en)
French (fr)
Other versions
CA2326654A1 (en
Inventor
Philip A. Beachy
Michael K. Cooper
Jeffrey A. Porter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27373925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2326654(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/090,622 external-priority patent/US6432970B2/en
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CA2326654A1 publication Critical patent/CA2326654A1/en
Application granted granted Critical
Publication of CA2326654C publication Critical patent/CA2326654C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)
CA2326654A 1998-04-09 1999-04-09 Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways Expired - Lifetime CA2326654C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8126398P 1998-04-09 1998-04-09
US8118698P 1998-04-09 1998-04-09
US60/081,263 1998-04-09
US60/081,186 1998-04-09
US09/090,622 1998-06-04
US09/090,622 US6432970B2 (en) 1998-04-09 1998-06-04 Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
PCT/US1999/007811 WO1999052534A1 (en) 1998-04-09 1999-04-09 Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways

Publications (2)

Publication Number Publication Date
CA2326654A1 CA2326654A1 (en) 1999-10-21
CA2326654C true CA2326654C (en) 2010-11-09

Family

ID=27373925

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2326654A Expired - Lifetime CA2326654C (en) 1998-04-09 1999-04-09 Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways

Country Status (6)

Country Link
EP (1) EP1067939B1 (enExample)
JP (2) JP5067986B2 (enExample)
AU (1) AU768130B2 (enExample)
CA (1) CA2326654C (enExample)
IL (2) IL138645A0 (enExample)
WO (1) WO1999052534A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
JP2002524528A (ja) 1998-09-11 2002-08-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ ヘッジホッグ様ポリペプチドによる肺組織の調節、およびそれに関する製剤および使用方法
AU2005201269C1 (en) * 1999-01-13 2008-09-04 Curis, Inc. Regulators of the PCT or smoothened pathway, compositions and uses related thereto
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
ES2233383T3 (es) * 1999-06-08 2005-06-16 Lorantis Limited Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog.
AU781524B2 (en) 1999-10-13 2005-05-26 Johns Hopkins University School Of Medicine, The Regulators of the hedgehog pathway, compositions and uses related thereto
IL133809A0 (en) * 1999-12-30 2001-04-30 Yeda Res & Dev Steroidal alkaloids and pharmaceutical compositions comprising them
WO2001098344A2 (en) * 2000-06-16 2001-12-27 Curis, Inc. Angiogenesis-modulating compositions and uses
WO2002030462A2 (en) * 2000-10-13 2002-04-18 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
RU2308948C2 (ru) * 2001-07-02 2007-10-27 ТАШ Шинан Применение циклопамина для лечения базально-клеточной эпителиомы (карциномы) и других опухолей
ES2534400T3 (es) * 2001-07-02 2015-04-22 Sinan Tas Uso de ciclopamina en el tratamiento de carcinoma de células basales y otros tumores
CA2452152A1 (en) * 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
US7655674B2 (en) 2002-04-22 2010-02-02 The Johns Hopkins University Modulators of hedgehog signaling pathways, compositions and uses related thereto
ES2403006T3 (es) * 2005-08-22 2013-05-13 The Johns Hopkins University Antagonistas de la vía Hedgehog para tratar enfermedades
JP2009209099A (ja) * 2008-03-05 2009-09-17 Kumamoto Univ 動脈硬化の予防・治療剤
JP5442717B2 (ja) 2008-04-29 2014-03-12 イーライ リリー アンド カンパニー 二置換フタラジンヘッジホッグ経路アンタゴニスト
PE20110433A1 (es) 2008-11-03 2011-07-09 Lilly Co Eli Antagonistas de la via hedgehog de ftalazina disustituida
EP2358703B1 (en) 2008-11-17 2013-12-25 Eli Lilly and Company Tetrasubstituted pyridazines hedgehog pathway antagonists
HRP20120762T1 (hr) 2008-11-17 2012-10-31 Eli Lilly And Company Tetrasupstituirani piridazini kao inhibitori hedgehog puta
JP2009143963A (ja) * 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
FR2948367A1 (fr) 2009-07-24 2011-01-28 Centre Nat Rech Scient Derives d'acyl-guanidines modulateurs de la voie de signalisation des proteines hedgehog
FR2967498B1 (fr) 2010-11-16 2015-01-02 Centre Nat Rech Scient Utilisation de derives de quinolinone comme outil de recherche
JP6001060B2 (ja) * 2011-06-06 2016-10-05 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 筋萎縮を阻害するための方法
FR2980477B1 (fr) 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
JP2014028835A (ja) * 2013-09-18 2014-02-13 Sinan Tas 基底細胞癌及び他の腫瘍の治療におけるシクロパミンの使用方法
CN106124677B (zh) * 2015-12-31 2018-01-16 广西梧州制药（集团）股份有限公司 一种平贝母药材指纹图谱的建立方法
CN109879933B (zh) * 2019-01-30 2023-06-06 河北科技大学 一类含磷酰基化合物及其应用
WO2022081661A1 (en) 2020-10-13 2022-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES258451A1 (es) 1960-04-01 1960-09-16 Abbott Lab Un metodo para obtener una composiciën farmaceutica en forma de dosificaciën oral
US3121043A (en) 1960-05-11 1964-02-11 Scient Associates Inc Sustained release pharmaceutical preparation and methods for making same
AT280497B (de) * 1968-03-05 1970-04-10 Chemie Linz Ag Verfahren zur Herstellung von neuen, ungesättigten Aminosteroiden
AT300214B (de) * 1970-04-24 1972-07-25 Chemie Linz Ag Verfahren zur Herstellung von Piperidylsteroiden
NZ193564A (en) * 1979-05-02 1985-01-31 Aruba Pty Ltd Steroid alkaloids from solanum sodomeum and pharmaceutical compositions
US5026882A (en) * 1988-12-23 1991-06-25 Smithkline Beecham Corporation Phosphinic acid substituted steroids as inhibitors of steroid 5α-reductase
ATE188036T1 (de) * 1990-01-18 2000-01-15 Cura Nominees Pty Ltd Glykoalkaloide
KR970005241B1 (ko) 1990-07-18 1997-04-14 주식회사 엘지화학 두발화장품 조성물
JPH04230696A (ja) * 1990-12-28 1992-08-19 Sanwa Shiyouyaku Kk 新規なステロイド系化合物および制癌剤
CA2184092A1 (en) 1994-02-25 1995-08-31 Thomas M. Jessell Dna encoding the vertebrate homolog of hedgehog, vhh-1, expressed by the notochord, and uses thereof
US6027882A (en) 1994-10-07 2000-02-22 The Regents Of The University Of California Patched genes and their use for diagnostics
AU7979998A (en) * 1997-06-20 1999-01-04 University Of Utah Research Foundation Use of plant-alkaloids to enhance innate immunity defense mechanisms

Also Published As

Publication number Publication date
AU3486099A (en) 1999-11-01
AU768130B2 (en) 2003-12-04
EP1067939A1 (en) 2001-01-17
IL138645A0 (en) 2001-10-31
WO1999052534A1 (en) 1999-10-21
CA2326654A1 (en) 1999-10-21
IL138645A (en) 2006-08-20
JP2002511415A (ja) 2002-04-16
JP2011037880A (ja) 2011-02-24
JP5067986B2 (ja) 2012-11-07
EP1067939B1 (en) 2015-09-16

Similar Documents

Publication Publication Date Title
CA2326654C (en) Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
US9427431B2 (en) Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US6432970B2 (en) Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US6867216B1 (en) Inhibitors of hedgehog signal pathways, compositions and uses related thereto
AU778866B2 (en) Regulators of the PCT or smoothened pathway, compositions and uses related thereto
AU2003231032B2 (en) Modulators of hedgehog signaling pathways, compositions and uses related thereto
EP1235851B1 (en) Regulators of the hedgehog pathway, compositions and uses related thereto
AU2005201269C1 (en) Regulators of the PCT or smoothened pathway, compositions and uses related thereto
AU2011224045A1 (en) Modulators of hedgehog signaling pathways, compositions and uses related thereto

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20190409